DRC Ebola Outbreak Claims 65 Lives, 246 Suspected Cases, Bundibugyo Strain Lacks Vaccine

Context The outbreak emerged in Ituri, a province that shares borders with Uganda and South Sudan and hosts active mining sites where workers travel frequently. Ebola spreads through direct contact with the blood, vomit, or other body fluids of infected individuals, or with contaminated surfaces such as those that people use during funeral preparations. Uganda’s health ministry confirmed a related case after a 59‑year‑old man who had traveled from DRC died in Kampala, prompting Africa CDC to call an urgent regional meeting involving DRC, Uganda, South Sudan, WHO and vaccine manufacturers.

Key Facts Officials report 65 fatalities and 246 suspected Ebola infections in Ituri so far. Laboratory testing identified the Bundibugyo subtype in 13 of 20 samples, confirming it as the causative agent; this strain surfaced previously in 2007 and 2012 but no licensed vaccine exists for it. In contrast, health officials target the Zaire strain—responsible for most past DRC outbreaks—with the rVSV‑ZEBOV vaccine, which showed 97.5 % efficacy in a ring‑vaccination RCT that enrolled over 4,000 contacts during the 2018‑2020 epidemic. The Bundibugyo outbreaks of 2007 and 2012 together resulted in fewer than 200 cases, indicating that the current cluster is already larger than those historic events.

What It Means The absence of a Bundibugyo‑specific vaccine means containment relies on rapid isolation, contact tracing, and safe burial practices, all of which high population mobility makes more difficult. Health workers are using personal protective equipment and setting up treatment centers in Mongwalu and Rwampara health zones, where most cases have occurred. Readers should avoid direct contact with bodily fluids of sick individuals, seek immediate care if symptoms such as fever, vomiting, or unexplained bleeding appear, and follow local health advisories. Watch for upcoming discussions among Africa CDC, WHO, and pharmaceutical companies about accelerating vaccine research for the Bundibugyo subtype and strengthening cross‑border surveillance to detect any spillover into Uganda or South Sudan.